Summary
Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (known as the mesothelium).
Malignant mesothelioma is a cancer of the thin tissue (mesothelium) that lines the lung, chest wall, and abdomen. The major risk factor for mesothelioma is asbestos exposure.
According to APO Research, The global Malignant Mesothelioma Therapeutic market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Malignant Mesothelioma Therapeutic is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Malignant Mesothelioma Therapeutic is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Malignant Mesothelioma Therapeutic is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Malignant Mesothelioma Therapeutic is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global companies of Malignant Mesothelioma Therapeutic include Eli Lilly, Teva, Sanofi, Bristol-Myers Squibb, Pfizer, Roche, Merck, Ono Pharmaceutical and Mylan, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Malignant Mesothelioma Therapeutic, market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Malignant Mesothelioma Therapeutic, also provides the revenue of main regions and countries. Of the upcoming market potential for Malignant Mesothelioma Therapeutic, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Malignant Mesothelioma Therapeutic revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Malignant Mesothelioma Therapeutic market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Malignant Mesothelioma Therapeutic revenue, projected growth trends, production technology, application and end-user industry.
Malignant Mesothelioma Therapeutic segment by Company
Eli Lilly
Teva
Sanofi
Bristol-Myers Squibb
Pfizer
Roche
Merck
Ono Pharmaceutical
Mylan
Fresenius Kabi
Sun Pharmaceuticals
Malignant Mesothelioma Therapeutic segment by Type
Pemetrexed
Cisplatin
Others
Malignant Mesothelioma Therapeutic segment by Application
Pleural Mesothelioma
Peritoneal Mesothelioma
Others
Malignant Mesothelioma Therapeutic segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Malignant Mesothelioma Therapeutic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Malignant Mesothelioma Therapeutic and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Malignant Mesothelioma Therapeutic.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Malignant Mesothelioma Therapeutic in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Malignant Mesothelioma Therapeutic company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Malignant Mesothelioma Therapeutic revenue, gross margin, and recent development, etc.
Chapter 8: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: Middle East, Africa, and Latin America type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
1 Market Overview
1.1 Product Definition
1.2 Malignant Mesothelioma Therapeutic Market by Type
1.2.1 Global Malignant Mesothelioma Therapeutic Market Size by Type, 2019 VS 2023 VS 2030
1.2.2 Pemetrexed
1.2.3 Cisplatin
1.2.4 Others
1.3 Malignant Mesothelioma Therapeutic Market by Application
1.3.1 Global Malignant Mesothelioma Therapeutic Market Size by Application, 2019 VS 2023 VS 2030
1.3.2 Pleural Mesothelioma
1.3.3 Peritoneal Mesothelioma
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Malignant Mesothelioma Therapeutic Market Dynamics
2.1 Malignant Mesothelioma Therapeutic Industry Trends
2.2 Malignant Mesothelioma Therapeutic Industry Drivers
2.3 Malignant Mesothelioma Therapeutic Industry Opportunities and Challenges
2.4 Malignant Mesothelioma Therapeutic Industry Restraints
3 Global Growth Perspective
3.1 Global Malignant Mesothelioma Therapeutic Market Perspective (2019-2030)
3.2 Global Malignant Mesothelioma Therapeutic Growth Trends by Region
3.2.1 Global Malignant Mesothelioma Therapeutic Market Size by Region: 2019 VS 2023 VS 2030
3.2.2 Global Malignant Mesothelioma Therapeutic Market Size by Region (2019-2024)
3.2.3 Global Malignant Mesothelioma Therapeutic Market Size by Region (2025-2030)
4 Competitive Landscape by Players
4.1 Global Malignant Mesothelioma Therapeutic Revenue by Players
4.1.1 Global Malignant Mesothelioma Therapeutic Revenue by Players (2019-2024)
4.1.2 Global Malignant Mesothelioma Therapeutic Revenue Market Share by Players (2019-2024)
4.1.3 Global Malignant Mesothelioma Therapeutic Players Revenue Share Top 10 and Top 5 in 2023
4.2 Global Malignant Mesothelioma Therapeutic Key Players Ranking, 2022 VS 2023 VS 2024
4.3 Global Malignant Mesothelioma Therapeutic Key Players Headquarters & Area Served
4.4 Global Malignant Mesothelioma Therapeutic Players, Product Type & Application
4.5 Global Malignant Mesothelioma Therapeutic Players Commercialization Time
4.6 Market Competitive Analysis
4.6.1 Global Malignant Mesothelioma Therapeutic Market CR5 and HHI
4.6.2 Global Top 5 and 10 Malignant Mesothelioma Therapeutic Players Market Share by Revenue in 2023
4.6.3 2023 Malignant Mesothelioma Therapeutic Tier 1, Tier 2, and Tier 3
5 Malignant Mesothelioma Therapeutic Market Size by Type
5.1 Global Malignant Mesothelioma Therapeutic Revenue by Type (2019 VS 2023 VS 2030)
5.2 Global Malignant Mesothelioma Therapeutic Revenue by Type (2019-2030)
5.3 Global Malignant Mesothelioma Therapeutic Revenue Market Share by Type (2019-2030)
6 Malignant Mesothelioma Therapeutic Market Size by Application
6.1 Global Malignant Mesothelioma Therapeutic Revenue by Application (2019 VS 2023 VS 2030)
6.2 Global Malignant Mesothelioma Therapeutic Revenue by Application (2019-2030)
6.3 Global Malignant Mesothelioma Therapeutic Revenue Market Share by Application (2019-2030)
7 Company Profiles
7.1 Eli Lilly
7.1.1 Eli Lilly Comapny Information
7.1.2 Eli Lilly Business Overview
7.1.3 Eli Lilly Malignant Mesothelioma Therapeutic Revenue and Gross Margin (2019-2024)
7.1.4 Eli Lilly Malignant Mesothelioma Therapeutic Product Portfolio
7.1.5 Eli Lilly Recent Developments
7.2 Teva
7.2.1 Teva Comapny Information
7.2.2 Teva Business Overview
7.2.3 Teva Malignant Mesothelioma Therapeutic Revenue and Gross Margin (2019-2024)
7.2.4 Teva Malignant Mesothelioma Therapeutic Product Portfolio
7.2.5 Teva Recent Developments
7.3 Sanofi
7.3.1 Sanofi Comapny Information
7.3.2 Sanofi Business Overview
7.3.3 Sanofi Malignant Mesothelioma Therapeutic Revenue and Gross Margin (2019-2024)
7.3.4 Sanofi Malignant Mesothelioma Therapeutic Product Portfolio
7.3.5 Sanofi Recent Developments
7.4 Bristol-Myers Squibb
7.4.1 Bristol-Myers Squibb Comapny Information
7.4.2 Bristol-Myers Squibb Business Overview
7.4.3 Bristol-Myers Squibb Malignant Mesothelioma Therapeutic Revenue and Gross Margin (2019-2024)
7.4.4 Bristol-Myers Squibb Malignant Mesothelioma Therapeutic Product Portfolio
7.4.5 Bristol-Myers Squibb Recent Developments
7.5 Pfizer
7.5.1 Pfizer Comapny Information
7.5.2 Pfizer Business Overview
7.5.3 Pfizer Malignant Mesothelioma Therapeutic Revenue and Gross Margin (2019-2024)
7.5.4 Pfizer Malignant Mesothelioma Therapeutic Product Portfolio
7.5.5 Pfizer Recent Developments
7.6 Roche
7.6.1 Roche Comapny Information
7.6.2 Roche Business Overview
7.6.3 Roche Malignant Mesothelioma Therapeutic Revenue and Gross Margin (2019-2024)
7.6.4 Roche Malignant Mesothelioma Therapeutic Product Portfolio
7.6.5 Roche Recent Developments
7.7 Merck
7.7.1 Merck Comapny Information
7.7.2 Merck Business Overview
7.7.3 Merck Malignant Mesothelioma Therapeutic Revenue and Gross Margin (2019-2024)
7.7.4 Merck Malignant Mesothelioma Therapeutic Product Portfolio
7.7.5 Merck Recent Developments
7.8 Ono Pharmaceutical
7.8.1 Ono Pharmaceutical Comapny Information
7.8.2 Ono Pharmaceutical Business Overview
7.8.3 Ono Pharmaceutical Malignant Mesothelioma Therapeutic Revenue and Gross Margin (2019-2024)
7.8.4 Ono Pharmaceutical Malignant Mesothelioma Therapeutic Product Portfolio
7.8.5 Ono Pharmaceutical Recent Developments
7.9 Mylan
7.9.1 Mylan Comapny Information
7.9.2 Mylan Business Overview
7.9.3 Mylan Malignant Mesothelioma Therapeutic Revenue and Gross Margin (2019-2024)
7.9.4 Mylan Malignant Mesothelioma Therapeutic Product Portfolio
7.9.5 Mylan Recent Developments
7.10 Fresenius Kabi
7.10.1 Fresenius Kabi Comapny Information
7.10.2 Fresenius Kabi Business Overview
7.10.3 Fresenius Kabi Malignant Mesothelioma Therapeutic Revenue and Gross Margin (2019-2024)
7.10.4 Fresenius Kabi Malignant Mesothelioma Therapeutic Product Portfolio
7.10.5 Fresenius Kabi Recent Developments
7.11 Sun Pharmaceuticals
7.11.1 Sun Pharmaceuticals Comapny Information
7.11.2 Sun Pharmaceuticals Business Overview
7.11.3 Sun Pharmaceuticals Malignant Mesothelioma Therapeutic Revenue and Gross Margin (2019-2024)
7.11.4 Sun Pharmaceuticals Malignant Mesothelioma Therapeutic Product Portfolio
7.11.5 Sun Pharmaceuticals Recent Developments
8 North America
8.1 North America Malignant Mesothelioma Therapeutic Revenue (2019-2030)
8.2 North America Malignant Mesothelioma Therapeutic Revenue by Type (2019-2030)
8.2.1 North America Malignant Mesothelioma Therapeutic Revenue by Type (2019-2024)
8.2.2 North America Malignant Mesothelioma Therapeutic Revenue by Type (2025-2030)
8.3 North America Malignant Mesothelioma Therapeutic Revenue Share by Type (2019-2030)
8.4 North America Malignant Mesothelioma Therapeutic Revenue by Application (2019-2030)
8.4.1 North America Malignant Mesothelioma Therapeutic Revenue by Application (2019-2024)
8.4.2 North America Malignant Mesothelioma Therapeutic Revenue by Application (2025-2030)
8.5 North America Malignant Mesothelioma Therapeutic Revenue Share by Application (2019-2030)
8.6 North America Malignant Mesothelioma Therapeutic Revenue by Country
8.6.1 North America Malignant Mesothelioma Therapeutic Revenue by Country (2019 VS 2023 VS 2030)
8.6.2 North America Malignant Mesothelioma Therapeutic Revenue by Country (2019-2024)
8.6.3 North America Malignant Mesothelioma Therapeutic Revenue by Country (2025-2030)
8.6.4 United States
8.6.5 Canada
9 Europe
9.1 Europe Malignant Mesothelioma Therapeutic Revenue (2019-2030)
9.2 Europe Malignant Mesothelioma Therapeutic Revenue by Type (2019-2030)
9.2.1 Europe Malignant Mesothelioma Therapeutic Revenue by Type (2019-2024)
9.2.2 Europe Malignant Mesothelioma Therapeutic Revenue by Type (2025-2030)
9.3 Europe Malignant Mesothelioma Therapeutic Revenue Share by Type (2019-2030)
9.4 Europe Malignant Mesothelioma Therapeutic Revenue by Application (2019-2030)
9.4.1 Europe Malignant Mesothelioma Therapeutic Revenue by Application (2019-2024)
9.4.2 Europe Malignant Mesothelioma Therapeutic Revenue by Application (2025-2030)
9.5 Europe Malignant Mesothelioma Therapeutic Revenue Share by Application (2019-2030)
9.6 Europe Malignant Mesothelioma Therapeutic Revenue by Country
9.6.1 Europe Malignant Mesothelioma Therapeutic Revenue by Country (2019 VS 2023 VS 2030)
9.6.2 Europe Malignant Mesothelioma Therapeutic Revenue by Country (2019-2024)
9.6.3 Europe Malignant Mesothelioma Therapeutic Revenue by Country (2025-2030)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
10 China
10.1 China Malignant Mesothelioma Therapeutic Revenue (2019-2030)
10.2 China Malignant Mesothelioma Therapeutic Revenue by Type (2019-2030)
10.2.1 China Malignant Mesothelioma Therapeutic Revenue by Type (2019-2024)
10.2.2 China Malignant Mesothelioma Therapeutic Revenue by Type (2025-2030)
10.3 China Malignant Mesothelioma Therapeutic Revenue Share by Type (2019-2030)
10.4 China Malignant Mesothelioma Therapeutic Revenue by Application (2019-2030)
10.4.1 China Malignant Mesothelioma Therapeutic Revenue by Application (2019-2024)
10.4.2 China Malignant Mesothelioma Therapeutic Revenue by Application (2025-2030)
10.5 China Malignant Mesothelioma Therapeutic Revenue Share by Application (2019-2030)
11 Asia (Excluding China)
11.1 Asia Malignant Mesothelioma Therapeutic Revenue (2019-2030)
11.2 Asia Malignant Mesothelioma Therapeutic Revenue by Type (2019-2030)
11.2.1 Asia Malignant Mesothelioma Therapeutic Revenue by Type (2019-2024)
11.2.2 Asia Malignant Mesothelioma Therapeutic Revenue by Type (2025-2030)
11.3 Asia Malignant Mesothelioma Therapeutic Revenue Share by Type (2019-2030)
11.4 Asia Malignant Mesothelioma Therapeutic Revenue by Application (2019-2030)
11.4.1 Asia Malignant Mesothelioma Therapeutic Revenue by Application (2019-2024)
11.4.2 Asia Malignant Mesothelioma Therapeutic Revenue by Application (2025-2030)
11.5 Asia Malignant Mesothelioma Therapeutic Revenue Share by Application (2019-2030)
11.6 Asia Malignant Mesothelioma Therapeutic Revenue by Country
11.6.1 Asia Malignant Mesothelioma Therapeutic Revenue by Country (2019 VS 2023 VS 2030)
11.6.2 Asia Malignant Mesothelioma Therapeutic Revenue by Country (2019-2024)
11.6.3 Asia Malignant Mesothelioma Therapeutic Revenue by Country (2025-2030)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 China Taiwan
11.6.9 Southeast Asia
12 Middle East, Africa, Latin America
12.1 MEALA Malignant Mesothelioma Therapeutic Revenue (2019-2030)
12.2 MEALA Malignant Mesothelioma Therapeutic Revenue by Type (2019-2030)
12.2.1 MEALA Malignant Mesothelioma Therapeutic Revenue by Type (2019-2024)
12.2.2 MEALA Malignant Mesothelioma Therapeutic Revenue by Type (2025-2030)
12.3 MEALA Malignant Mesothelioma Therapeutic Revenue Share by Type (2019-2030)
12.4 MEALA Malignant Mesothelioma Therapeutic Revenue by Application (2019-2030)
12.4.1 MEALA Malignant Mesothelioma Therapeutic Revenue by Application (2019-2024)
12.4.2 MEALA Malignant Mesothelioma Therapeutic Revenue by Application (2025-2030)
12.5 MEALA Malignant Mesothelioma Therapeutic Revenue Share by Application (2019-2030)
12.6 MEALA Malignant Mesothelioma Therapeutic Revenue by Country
12.6.1 MEALA Malignant Mesothelioma Therapeutic Revenue by Country (2019 VS 2023 VS 2030)
12.6.2 MEALA Malignant Mesothelioma Therapeutic Revenue by Country (2019-2024)
12.6.3 MEALA Malignant Mesothelioma Therapeutic Revenue by Country (2025-2030)
12.6.4 Mexico
12.6.5 Brazil
12.6.6 Israel
12.6.7 Argentina
12.6.8 Colombia
12.6.9 Turkey
12.6.10 Saudi Arabia
12.6.11 UAE
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
List of Tables
Table 1. Global Malignant Mesothelioma Therapeutic Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Table 1. Pemetrexed Major Manufacturers
Table 2. Cisplatin Major Manufacturers
Table 3. Others Major Manufacturers
Table 4. Global Malignant Mesothelioma Therapeutic Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Table 5. Pleural Mesothelioma Major Manufacturers
Table 6. Peritoneal Mesothelioma Major Manufacturers
Table 7. Others Major Manufacturers
Table 8. Malignant Mesothelioma Therapeutic Industry Trends
Table 9. Malignant Mesothelioma Therapeutic Industry Drivers
Table 10. Malignant Mesothelioma Therapeutic Industry Opportunities and Challenges
Table 11. Malignant Mesothelioma Therapeutic Industry Restraints
Table 12. Global Malignant Mesothelioma Therapeutic Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
Table 13. Global Malignant Mesothelioma Therapeutic Market Size by Region (2019-2024) & (US$ Million)
Table 14. Global Malignant Mesothelioma Therapeutic Market Share by Region (2019-2024)
Table 15. Global Malignant Mesothelioma Therapeutic Market Size by Region (2025-2030) & (US$ Million)
Table 16. Global Malignant Mesothelioma Therapeutic Market Share by Region (2025-2030)
Table 17. Global Malignant Mesothelioma Therapeutic Revenue by Players (US$ Million) & (2019-2024)
Table 18. Global Malignant Mesothelioma Therapeutic Revenue Market Share by Players (2019-2024)
Table 19. Global Malignant Mesothelioma Therapeutic Key Players Ranking, 2022 VS 2023 VS 2024
Table 20. Global Malignant Mesothelioma Therapeutic Key Players Headquarters & Area Served
Table 21. Global Malignant Mesothelioma Therapeutic Players, Product Type & Application
Table 22. Global Malignant Mesothelioma Therapeutic Players Commercialization Time
Table 23. Global Players Market Concentration Ratio (CR5 and HHI)
Table 24. Global Malignant Mesothelioma Therapeutic by Players Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2023)
Table 25. Global Malignant Mesothelioma Therapeutic Revenue by Type 2019 VS 2023 VS 2030 (US$ Million)
Table 26. Global Malignant Mesothelioma Therapeutic Revenue by Type (2019-2024) & (US$ Million)
Table 27. Global Malignant Mesothelioma Therapeutic Revenue by Type (2025-2030) & (US$ Million)
Table 28. Global Malignant Mesothelioma Therapeutic Revenue Market Share by Type (2019-2024) & (US$ Million)
Table 29. Global Malignant Mesothelioma Therapeutic Revenue Market Share by Type (2025-2030) & (US$ Million)
Table 30. Global Malignant Mesothelioma Therapeutic Revenue by Application 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Global Malignant Mesothelioma Therapeutic Revenue by Application (2019-2024) & (US$ Million)
Table 32. Global Malignant Mesothelioma Therapeutic Revenue by Application (2025-2030) & (US$ Million)
Table 33. Global Malignant Mesothelioma Therapeutic Revenue Market Share by Application (2019-2024) & (US$ Million)
Table 34. Global Malignant Mesothelioma Therapeutic Revenue Market Share by Application (2025-2030) & (US$ Million)
Table 35. Eli Lilly Company Information
Table 36. Eli Lilly Business Overview
Table 37. Eli Lilly Malignant Mesothelioma Therapeutic Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 38. Eli Lilly Malignant Mesothelioma Therapeutic Product Portfolio
Table 39. Eli Lilly Recent Development
Table 40. Teva Company Information
Table 41. Teva Business Overview
Table 42. Teva Malignant Mesothelioma Therapeutic Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 43. Teva Malignant Mesothelioma Therapeutic Product Portfolio
Table 44. Teva Recent Development
Table 45. Sanofi Company Information
Table 46. Sanofi Business Overview
Table 47. Sanofi Malignant Mesothelioma Therapeutic Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 48. Sanofi Malignant Mesothelioma Therapeutic Product Portfolio
Table 49. Sanofi Recent Development
Table 50. Bristol-Myers Squibb Company Information
Table 51. Bristol-Myers Squibb Business Overview
Table 52. Bristol-Myers Squibb Malignant Mesothelioma Therapeutic Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 53. Bristol-Myers Squibb Malignant Mesothelioma Therapeutic Product Portfolio
Table 54. Bristol-Myers Squibb Recent Development
Table 55. Pfizer Company Information
Table 56. Pfizer Business Overview
Table 57. Pfizer Malignant Mesothelioma Therapeutic Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 58. Pfizer Malignant Mesothelioma Therapeutic Product Portfolio
Table 59. Pfizer Recent Development
Table 60. Roche Company Information
Table 61. Roche Business Overview
Table 62. Roche Malignant Mesothelioma Therapeutic Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 63. Roche Malignant Mesothelioma Therapeutic Product Portfolio
Table 64. Roche Recent Development
Table 65. Merck Company Information
Table 66. Merck Business Overview
Table 67. Merck Malignant Mesothelioma Therapeutic Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 68. Merck Malignant Mesothelioma Therapeutic Product Portfolio
Table 69. Merck Recent Development
Table 70. Ono Pharmaceutical Company Information
Table 71. Ono Pharmaceutical Business Overview
Table 72. Ono Pharmaceutical Malignant Mesothelioma Therapeutic Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 73. Ono Pharmaceutical Malignant Mesothelioma Therapeutic Product Portfolio
Table 74. Ono Pharmaceutical Recent Development
Table 75. Mylan Company Information
Table 76. Mylan Business Overview
Table 77. Mylan Malignant Mesothelioma Therapeutic Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 78. Mylan Malignant Mesothelioma Therapeutic Product Portfolio
Table 79. Mylan Recent Development
Table 80. Fresenius Kabi Company Information
Table 81. Fresenius Kabi Business Overview
Table 82. Fresenius Kabi Malignant Mesothelioma Therapeutic Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 83. Fresenius Kabi Malignant Mesothelioma Therapeutic Product Portfolio
Table 84. Fresenius Kabi Recent Development
Table 85. Sun Pharmaceuticals Company Information
Table 86. Sun Pharmaceuticals Business Overview
Table 87. Sun Pharmaceuticals Malignant Mesothelioma Therapeutic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Sun Pharmaceuticals Malignant Mesothelioma Therapeutic Product Portfolio
Table 89. Sun Pharmaceuticals Recent Development
Table 90. North America Malignant Mesothelioma Therapeutic Revenue by Type (2019-2024) & (US$ Million)
Table 91. North America Malignant Mesothelioma Therapeutic Revenue by Application (2019-2024) & (US$ Million)
Table 92. North America Malignant Mesothelioma Therapeutic Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 93. North America Malignant Mesothelioma Therapeutic Revenue by Country (2019-2024) & (US$ Million)
Table 94. North America Malignant Mesothelioma Therapeutic Revenue by Country (2025-2030) & (US$ Million)
Table 95. Europe Malignant Mesothelioma Therapeutic Revenue by Type (2019-2024) & (US$ Million)
Table 96. Europe Malignant Mesothelioma Therapeutic Revenue by Application (2019-2024) & (US$ Million)
Table 97. Europe Malignant Mesothelioma Therapeutic Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 98. Europe Malignant Mesothelioma Therapeutic Revenue by Country (2019-2024) & (US$ Million)
Table 99. Europe Malignant Mesothelioma Therapeutic Revenue by Country (2025-2030) & (US$ Million)
Table 100. China Malignant Mesothelioma Therapeutic Revenue by Type (2019-2024) & (US$ Million)
Table 101. China Malignant Mesothelioma Therapeutic Revenue by Application (2019-2024) & (US$ Million)
Table 102. Asia Malignant Mesothelioma Therapeutic Revenue by Type (2019-2024) & (US$ Million)
Table 103. Asia Malignant Mesothelioma Therapeutic Revenue by Application (2019-2024) & (US$ Million)
Table 104. Asia Malignant Mesothelioma Therapeutic Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 105. Asia Malignant Mesothelioma Therapeutic Revenue by Country (2019-2024) & (US$ Million)
Table 106. Asia Malignant Mesothelioma Therapeutic Revenue by Country (2025-2030) & (US$ Million)
Table 107. MEALA Malignant Mesothelioma Therapeutic Revenue by Type (2019-2024) & (US$ Million)
Table 108. MEALA Malignant Mesothelioma Therapeutic Revenue by Application (2019-2024) & (US$ Million)
Table 109. MEALA Malignant Mesothelioma Therapeutic Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 110. MEALA Malignant Mesothelioma Therapeutic Revenue by Country (2019-2024) & (US$ Million)
Table 111. MEALA Malignant Mesothelioma Therapeutic Revenue by Country (2025-2030) & (US$ Million)
Table 112. Research Programs/Design for This Report
Table 113. Authors List of This Report
Table 114. Secondary Sources
Table 115. Primary Sources
List of Figures
Figure 1. Malignant Mesothelioma Therapeutic Product Picture
Figure 2. Global Malignant Mesothelioma Therapeutic Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global Malignant Mesothelioma Therapeutic Market Size Share 2019 VS 2023 VS 2030
Figure 4. Pemetrexed Picture
Figure 5. Cisplatin Picture
Figure 6. Others Picture
Figure 7. Global Malignant Mesothelioma Therapeutic Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Figure 8. Global Malignant Mesothelioma Therapeutic Market Size Share 2019 VS 2023 VS 2030
Figure 9. Pleural Mesothelioma Picture
Figure 10. Peritoneal Mesothelioma Picture
Figure 11. Others Picture
Figure 12. Global Malignant Mesothelioma Therapeutic Market Size (US$ Million) & (2019-2030)
Figure 13. Global Malignant Mesothelioma Therapeutic Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global Malignant Mesothelioma Therapeutic Market Share by Region: 2019 VS 2023 VS 2030
Figure 15. Global Malignant Mesothelioma Therapeutic Players Revenue Share Top 10 and Top 5 in 2023
Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 17. Global Malignant Mesothelioma Therapeutic Revenue by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 18. Global Malignant Mesothelioma Therapeutic Revenue Market Share 2019 VS 2023 VS 2030
Figure 19. Global Malignant Mesothelioma Therapeutic Revenue Market Share by Type (2019-2030)
Figure 20. Global Malignant Mesothelioma Therapeutic Revenue by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 21. Global Malignant Mesothelioma Therapeutic Revenue Market Share by Application (2019 VS 2023 VS 2030)
Figure 22. Global Malignant Mesothelioma Therapeutic Revenue Market Share by Application (2019-2030)
Figure 23. North America Malignant Mesothelioma Therapeutic Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 24. North America Malignant Mesothelioma Therapeutic Revenue by Type (2025-2030) & (US$ Million)
Figure 25. North America Malignant Mesothelioma Therapeutic Revenue Share by Type (2019-2030)
Figure 26. North America Malignant Mesothelioma Therapeutic Revenue by Application (2025-2030) & (US$ Million)
Figure 27. North America Malignant Mesothelioma Therapeutic Revenue Share by Application (2019-2030)
Figure 28. North America Malignant Mesothelioma Therapeutic Revenue Share by Country (2019-2030)
Figure 29. United States Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 30. Canada Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 31. Europe Malignant Mesothelioma Therapeutic Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 32. Europe Malignant Mesothelioma Therapeutic Revenue by Type (2025-2030) & (US$ Million)
Figure 33. Europe Malignant Mesothelioma Therapeutic Revenue Share by Type (2019-2030)
Figure 34. Europe Malignant Mesothelioma Therapeutic Revenue by Application (2025-2030) & (US$ Million)
Figure 35. Europe Malignant Mesothelioma Therapeutic Revenue Share by Application (2019-2030)
Figure 36. Europe Malignant Mesothelioma Therapeutic Revenue Share by Country (2019-2030)
Figure 37. Germany Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 38. France Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 39. U.K. Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 40. Italy Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 41. Russia Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 42. Nordic Countries Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 43. China Malignant Mesothelioma Therapeutic Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 44. China Malignant Mesothelioma Therapeutic Revenue by Type (2025-2030) & (US$ Million)
Figure 45. China Malignant Mesothelioma Therapeutic Revenue Share by Type (2019-2030)
Figure 46. China Malignant Mesothelioma Therapeutic Revenue by Application (2025-2030) & (US$ Million)
Figure 47. China Malignant Mesothelioma Therapeutic Revenue Share by Application (2019-2030)
Figure 48. Asia Malignant Mesothelioma Therapeutic Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 49. Asia Malignant Mesothelioma Therapeutic Revenue by Type (2025-2030) & (US$ Million)
Figure 50. Asia Malignant Mesothelioma Therapeutic Revenue Share by Type (2019-2030)
Figure 51. Asia Malignant Mesothelioma Therapeutic Revenue by Application (2025-2030) & (US$ Million)
Figure 52. Asia Malignant Mesothelioma Therapeutic Revenue Share by Application (2019-2030)
Figure 53. Asia Malignant Mesothelioma Therapeutic Revenue Share by Country (2019-2030)
Figure 54. Japan Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 55. South Korea Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 56. India Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 57. Australia Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 58. China Taiwan Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 59. Southeast Asia Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 60. MEALA Malignant Mesothelioma Therapeutic Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 61. MEALA Malignant Mesothelioma Therapeutic Revenue by Type (2025-2030) & (US$ Million)
Figure 62. MEALA Malignant Mesothelioma Therapeutic Revenue Share by Type (2019-2030)
Figure 63. MEALA Malignant Mesothelioma Therapeutic Revenue by Application (2025-2030) & (US$ Million)
Figure 64. MEALA Malignant Mesothelioma Therapeutic Revenue Share by Application (2019-2030)
Figure 65. MEALA Malignant Mesothelioma Therapeutic Revenue Share by Country (2019-2030)
Figure 66. Mexico Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 67. South Korea Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 68. Brazil Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 69. Israel Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 70. Argentina Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 71. Colombia Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 72. Turkey Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 73. Saudi Arabia Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 74. UAE Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 75. Years Considered
Figure 76. Research Process
Figure 77. Key Executives Interviewed
